- Home
- CAC vs PHVS Comparison
CAC vs PHVS Comparison
Compare CAC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- PHVS
- Stock Information
- Founded
- CAC 1875
- PHVS 2015
- Country
- CAC United States
- PHVS Switzerland
- Employees
- CAC N/A
- PHVS N/A
- Industry
- CAC Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- PHVS Health Care
- Exchange
- CAC Nasdaq
- PHVS Nasdaq
- Market Cap
- CAC N/A
- PHVS 909.5M
- IPO Year
- CAC 1997
- PHVS 2021
- Fundamental
- Price
- CAC $39.34
- PHVS $16.60
- Analyst Decision
- CAC Hold
- PHVS Strong Buy
- Analyst Count
- CAC 3
- PHVS 5
- Target Price
- CAC $47.33
- PHVS $39.20
- AVG Volume (30 Days)
- CAC 54.8K
- PHVS 59.4K
- Earning Date
- CAC 05-06-2025
- PHVS 05-13-2025
- Dividend Yield
- CAC 4.27%
- PHVS N/A
- EPS Growth
- CAC 2.54
- PHVS N/A
- EPS
- CAC 3.09
- PHVS N/A
- Revenue
- CAC $184,324,000.00
- PHVS N/A
- Revenue This Year
- CAC $40.83
- PHVS N/A
- Revenue Next Year
- CAC $5.29
- PHVS N/A
- P/E Ratio
- CAC $12.75
- PHVS N/A
- Revenue Growth
- CAC 13.26
- PHVS N/A
- 52 Week Low
- CAC $30.78
- PHVS $11.51
- 52 Week High
- CAC $50.07
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- CAC 45.56
- PHVS 52.79
- Support Level
- CAC $39.33
- PHVS $15.46
- Resistance Level
- CAC $40.32
- PHVS $16.50
- Average True Range (ATR)
- CAC 0.72
- PHVS 1.04
- MACD
- CAC -0.15
- PHVS -0.10
- Stochastic Oscillator
- CAC 24.14
- PHVS 75.33
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.